| 1295
NITITHAM eT Al. present understanding of IL17 pathway genetics in psoriasis does not account for the observation that close to 90% of patients show a major response to anti-IL17A or anti-IL17RA drugs. [4] [5] [6] Most disease-modifying variants do not reside in or near genes but instead in regulatory elements as far as 200 kb from the actual gene locus. [7] Such long-range interaction (LRI) variants have been mapped by as DNA hypersensitive sites (DHS), histone marks indicating active transcriptional activity (H3K27Ac) or expression quantitative trait loci (eQTL). Although available databases do not fully represent key cell types driving psoriasis activity (γ/δ T cells, Th17 subsets, dermal fibroblasts), they do allow preliminary mapping of putative LRI sites.
| QUE S TIONS ADDRE SS ED
We here focussed on four key genes as follows: IL23R, IL17A and IL17RA as genes encoding direct drug targets and TRAF3IP2, as this gene exhibits the strongest genetic IL17 pathway association.
Blocking the activity of proteins including IL23R, IL17A and IL17RA inhibits the psoriasis phenotype. 
| E XPERIMENTAL DE S I G N
Due to space constraints, all Methods have been placed into the Supplement (section "Supplementary Methods").
| RE SULTS

| Disruptive IL17 pathway variants are common but not universally associated with psoriasis risk
A large Chinese exome study reported the association of the variant Gly149Arg in the IL23R gene with psoriasis. [8] A GWAS analysis of a similarly sized Caucasian cohort did not replicate this, but instead reported the association of another variant in the same gene (IL23R:p. Arg381Gln). [9] Conversely, the latter study reported the association of two coding variants in the TRAF3IP2 gene not seen in the Chinese data set. [9] By data mining of global exome variant data, [10] we found that the Chinese and European data sets, respectively, detected those risk alleles most common in each population ( Figure S3a Pro562Gln mutation, which is highly prevalent in East Asians ( Figure   S3c ). In addition, Europeans, but not Asians, exhibit two disruptive and evolutionary conserved mutations in IL17F that would have been detectable by Dand and Mucha [9] ( Figure S3d ). Of interest, the IL17A gene exhibits a notable scarcity of disruptive variants with the exception of one mutation relatively abundant in Hispanics, approximately 1% ( Figure S3b ). Independent of evolutionary protection, these mutations (exception: IL17F:p.Val155Ile) are predicted to be deleterious using the SIFT tool (http://sift.bii.a-star.edu.sg). Table S3 ). C, same as in B for region R2. D, LRI between the TRAF3IP2 promoter (light blue box on the right) and the TRAF3IP2 antisense (AS) promoter (marked R3). E, Closeup of the R3 region showing H3K27Ac enhancer as well as DNAse hypersensitivity marks
Taken together, these data show that, while some variants directly disrupting IL23R and TRAF3IP2 do show the expected genetic association with psoriasis, many frequent IL17 pathway mutations do not. Therefore, genetic risk affecting psoriasis may reside in LRI sites acting from a distance.
| A LRI site regulating IL17RA expression
To detect LRI sites, we mined available data sets for LRI regions, scanning 200-kb intervals around IL17A, IL17RA, IL23R and TRAF3IP2.
As shown in Figure 1A , we identified evidence for two LRIs associated with IL17RA promoter activity in multiple cell lines based on CHIA-PET chromatin precipitation (labelled R1, R2, respectively). At higher resolution, both R1 and R2 showed strong H3K27Ac histone marks as well as DNAse hypersensitivity, confirming active enhancer status ( Figure 1B,C) . Furthermore, both R1 and R2 contain SNPs independently identified as eQTL regulating IL17RA gene expression (see [11] , for details S2 data file eQTL). An additional independent eQTL data set (GTex) also exhibits eQTL signals in R2, as well as an extensive cluster of eQTL signals within both R1 and R2 (bottom of Figure 1B ,C, respectively, complete GTex data in Figure S1 ). Taken 
| Long-range interaction of the TRAF3IP2 antisense promoter with TRAF3IP2
We also found strong evidence for LRI between the TRAF3IP2 promoter and the TRAF3IP2-AS1 (antisense) promoter based on CHIA-PET ( Figure 1D , region labelled "R3"). R3 is also highly enriched both for H3K27Ac and DHS marks ( Figure 1E ), consistent with active enhancer status. Again, two SNPs residing within R3, rs61269242 and rs1407644, have independently been identified as eQTL for TRAF3IP expression (S2 data file eQTL). In further independent support, the TRAF3IP2/TRAF3IP2-AS1 pair has been identified as a gene/natural antisense pair in a recent study on breast cancer. [12] Taken together, these data strongly suggest that TRAF3IP2 transcription is regulated by the abundance of its antisense product.
| Psoriasis cohort
To test the association of these novel putative regulatory sites with psoriasis, we assembled a discovery cohort based on a north-east Scottish demographic. The clinical characteristics of the cohort are shown in Table S3 . The Tayside cohort represents a mix of approximately 75%
HLA-Cw6+ and 25% HLA-Cw6-patients. Accordingly, the majority of patients (67%) exhibit age at onset >40 years. The cohort is also marked by a high median age (63 years) and high female percentage (54%). In addition, it is heterogeneous in terms of prior treatment (half of the patient naïve with respect to systemic treatments). Taken together, the Tayside/Scotland psoriasis cohort is distinct from previously reported cohorts, thereby broadening the genetic coverage of psoriasis.
| Genetic associations of IL17 signalling variants
We initially performed a single-point association analysis of the Tayside cohort spanning 200 kb to either side of the transcriptional start site of each of the candidate genes. As shown in Table S4 , we replicated the strong association previously observed with TRAF3IP2.
We also identified association with the eQTL rs71562294 mapping to the region R3 within the TRAF3IP2 antisense (AS1) promoter (Table 1, S2 data file eQTL). In addition, we identified two strongly associated SNPs located within 4 kb of the R1 LRI region regulating IL17RA (Table 1 ; Figure 1B marked by yellow lines and arrows). We did not detect association with the previously reported SNP rs11209026 at the IL23R gene locus. [13] We did identify significant association of SNPs in a putative enhancer 20 kb upstream of IL17A which, however, only replicated in one of three other cohorts (Table S2 , Figure S4 ) despite comparable allele frequencies (Table S5) artifact. Thus, the present data identify novel associations at the distant IL17RA enhancer (R1) as well as a putative enhancer for TRAF3IP2 located 200 kb downstream TRAF3IP2-AS1 and confirm significant genetic association of single SNPs located within TRAF3IP2.
| CONCLUSION
We here show that mutations disrupting IL17RA, IL17A and IL23R are common but do not necessarily affect psoriasis risk status, while drugs disrupting the proteins encoded by these same genes massively affect phenotype expression. This apparent paradox suggests that genetic risk for psoriasis may reside in LRI sites regulating these genes from a distance.
We identify regions R1 and R2 as novel LRI enhancers for IL17RA.
In line with these findings, two SNPs within 5-8 kb of R1 are associated with psoriasis in our novel discovery cohort. We also identify a pair by Ref., [12] rs71562294 located within the TRAF3IP-AS1 promoter may well regulate TRAF3IP2 protein abundance.
For IL17A itself, we observed a strikingly Th17-selective enhancer ( Figure S2 ), which, in fact, exhibited association with psoriasis in the Scottish cohort, as well as a US-based replication cohort but not in additional replication cohorts (Results S1, S2). Comprehensive discovery of long-range interacting regions for Th17 and γ/δ-T cellspecific genes including IL17A, IL17F and IL23R will require DHS, histone and eQTL data obtained in these cell types. Results S1 Association of candidate cis-acting SNP combinations. 
